Global Antisense Oligonucleotides Drugs for ATTR Market Growth 2026-2032

July 2026 | 79 pages | ID: G21C7BFB5E78EN
LP Information

Abstracts

The global Antisense Oligonucleotides Drugs for ATTR market size is predicted to grow from US$ million in 2025 to US$ million in 2032; it is expected to grow at a CAGR of %from 2026 to 2032.

Antisense oligonucleotide(ASO)drugs represent a groundbreaking approach for treating transthyretin amyloidosis(ATTR),a condition characterized by the accumulation of misfolded transthyretin proteins that lead to organ damage.These ASO drugs work by targeting and degrading the mRNA that encodes for transthyretin,thus reducing its production at the source.

United States market for Antisense Oligonucleotides Drugs for ATTR is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.

China market for Antisense Oligonucleotides Drugs for ATTR is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.

Europe market for Antisense Oligonucleotides Drugs for ATTR is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.

Global key Antisense Oligonucleotides Drugs for ATTR players cover Akcea Therapeutics, AstraZeneca, Ionis Pharmaceuticals, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.

LP Information, Inc. (LPI) ' newest research report, the ?Antisense Oligonucleotides Drugs for ATTR Industry Forecast? looks at past sales and reviews total world Antisense Oligonucleotides Drugs for ATTR sales in 2025, providing a comprehensive analysis by region and market sector of projected Antisense Oligonucleotides Drugs for ATTR sales for 2026 through 2032. With Antisense Oligonucleotides Drugs for ATTR sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Antisense Oligonucleotides Drugs for ATTR industry.

This Insight Report provides a comprehensive analysis of the global Antisense Oligonucleotides Drugs for ATTR landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Antisense Oligonucleotides Drugs for ATTR portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Antisense Oligonucleotides Drugs for ATTR market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Antisense Oligonucleotides Drugs for ATTR and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Antisense Oligonucleotides Drugs for ATTR.

This report presents a comprehensive overview, market shares, and growth opportunities of Antisense Oligonucleotides Drugs for ATTR market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

• Inotersen
• Eplontersen
• Other

Segmentation by Application:

• Hospital and Clinic
• Retail Pharmacies
• Other

This report also splits the market by region:

• Americas
• United States
• Canada
• Mexico
• Brazil
• APAC
• China
• Japan
• Korea
• Southeast Asia
• India
• Australia
• Europe
• Germany
• France
• UK
• Italy
• Russia
• Middle East & Africa
• Egypt
• South Africa
• Israel
• Turkey
• GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

• Akcea Therapeutics
• AstraZeneca
• Ionis Pharmaceuticals

Key Questions Addressed in this Report

• What is the 10-year outlook for the global Antisense Oligonucleotides Drugs for ATTR market?
• What factors are driving Antisense Oligonucleotides Drugs for ATTR market growth, globally and by region?
• Which technologies are poised for the fastest growth by market and region?
• How do Antisense Oligonucleotides Drugs for ATTR market opportunities vary by end market size?
• How does Antisense Oligonucleotides Drugs for ATTR break out by Type, by Application?

Contents

1 SCOPE OF THE REPORT

1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview
  2.1.1 Global Antisense Oligonucleotides Drugs for ATTR Annual Sales 2021-2032
  2.1.2 World Current & Future Analysis for Antisense Oligonucleotides Drugs for ATTR by Geographic Region, 2021, 2025 & 2032
  2.1.3 World Current & Future Analysis for Antisense Oligonucleotides Drugs for ATTR by Country/Region, 2021, 2025 & 2032
2.2 Antisense Oligonucleotides Drugs for ATTR Segment by Type
  2.2.1 Inotersen
  2.2.2 Eplontersen
  2.2.3 Other
  2.2.4 Antisense Oligonucleotides Drugs for ATTR Sales by Type
    2.2.4.1 Global Antisense Oligonucleotides Drugs for ATTR Sales Market Share by Type (2021-2026)
    2.2.4.2 Global Antisense Oligonucleotides Drugs for ATTR Revenue and Market Share by Type (2021-2026)
    2.2.4.3 Global Antisense Oligonucleotides Drugs for ATTR Sale Price by Type (2021-2026)
2.3 Antisense Oligonucleotides Drugs for ATTR Segment by Application
  2.3.1 Hospital and Clinic
  2.3.2 Retail Pharmacies
  2.3.3 Other
  2.3.4 Antisense Oligonucleotides Drugs for ATTR Sales by Application
    2.3.4.1 Global Antisense Oligonucleotides Drugs for ATTR Sale Market Share by Application (2021-2026)
    2.3.4.2 Global Antisense Oligonucleotides Drugs for ATTR Revenue and Market Share by Application (2021-2026)
    2.3.4.3 Global Antisense Oligonucleotides Drugs for ATTR Sale Price by Application (2021-2026)

3 GLOBAL BY COMPANY

3.1 Global Antisense Oligonucleotides Drugs for ATTR Breakdown Data by Company
  3.1.1 Global Antisense Oligonucleotides Drugs for ATTR Annual Sales by Company (2021-2026)
  3.1.2 Global Antisense Oligonucleotides Drugs for ATTR Sales Market Share by Company (2021-2026)
3.2 Global Antisense Oligonucleotides Drugs for ATTR Annual Revenue by Company (2021-2026)
  3.2.1 Global Antisense Oligonucleotides Drugs for ATTR Revenue by Company (2021-2026)
  3.2.2 Global Antisense Oligonucleotides Drugs for ATTR Revenue Market Share by Company (2021-2026)
3.3 Global Antisense Oligonucleotides Drugs for ATTR Sale Price by Company
3.4 Key Manufacturers Antisense Oligonucleotides Drugs for ATTR Producing Area Distribution, Sales Area, Product Type
  3.4.1 Key Manufacturers Antisense Oligonucleotides Drugs for ATTR Product Location Distribution
  3.4.2 Players Antisense Oligonucleotides Drugs for ATTR Products Offered
3.5 Market Concentration Rate Analysis
  3.5.1 Competition Landscape Analysis
  3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy

4 WORLD HISTORIC REVIEW FOR ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR BY GEOGRAPHIC REGION

4.1 World Historic Antisense Oligonucleotides Drugs for ATTR Market Size by Geographic Region (2021-2026)
  4.1.1 Global Antisense Oligonucleotides Drugs for ATTR Annual Sales by Geographic Region (2021-2026)
  4.1.2 Global Antisense Oligonucleotides Drugs for ATTR Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Antisense Oligonucleotides Drugs for ATTR Market Size by Country/Region (2021-2026)
  4.2.1 Global Antisense Oligonucleotides Drugs for ATTR Annual Sales by Country/Region (2021-2026)
  4.2.2 Global Antisense Oligonucleotides Drugs for ATTR Annual Revenue by Country/Region (2021-2026)
4.3 Americas Antisense Oligonucleotides Drugs for ATTR Sales Growth
4.4 APAC Antisense Oligonucleotides Drugs for ATTR Sales Growth
4.5 Europe Antisense Oligonucleotides Drugs for ATTR Sales Growth
4.6 Middle East & Africa Antisense Oligonucleotides Drugs for ATTR Sales Growth

5 AMERICAS

5.1 Americas Antisense Oligonucleotides Drugs for ATTR Sales by Country
  5.1.1 Americas Antisense Oligonucleotides Drugs for ATTR Sales by Country (2021-2026)
  5.1.2 Americas Antisense Oligonucleotides Drugs for ATTR Revenue by Country (2021-2026)
5.2 Americas Antisense Oligonucleotides Drugs for ATTR Sales by Type (2021-2026)
5.3 Americas Antisense Oligonucleotides Drugs for ATTR Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil

6 APAC

6.1 APAC Antisense Oligonucleotides Drugs for ATTR Sales by Region
  6.1.1 APAC Antisense Oligonucleotides Drugs for ATTR Sales by Region (2021-2026)
  6.1.2 APAC Antisense Oligonucleotides Drugs for ATTR Revenue by Region (2021-2026)
6.2 APAC Antisense Oligonucleotides Drugs for ATTR Sales by Type (2021-2026)
6.3 APAC Antisense Oligonucleotides Drugs for ATTR Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan

7 EUROPE

7.1 Europe Antisense Oligonucleotides Drugs for ATTR by Country
  7.1.1 Europe Antisense Oligonucleotides Drugs for ATTR Sales by Country (2021-2026)
  7.1.2 Europe Antisense Oligonucleotides Drugs for ATTR Revenue by Country (2021-2026)
7.2 Europe Antisense Oligonucleotides Drugs for ATTR Sales by Type (2021-2026)
7.3 Europe Antisense Oligonucleotides Drugs for ATTR Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Antisense Oligonucleotides Drugs for ATTR by Country
  8.1.1 Middle East & Africa Antisense Oligonucleotides Drugs for ATTR Sales by Country (2021-2026)
  8.1.2 Middle East & Africa Antisense Oligonucleotides Drugs for ATTR Revenue by Country (2021-2026)
8.2 Middle East & Africa Antisense Oligonucleotides Drugs for ATTR Sales by Type (2021-2026)
8.3 Middle East & Africa Antisense Oligonucleotides Drugs for ATTR Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Antisense Oligonucleotides Drugs for ATTR
10.3 Manufacturing Process Analysis of Antisense Oligonucleotides Drugs for ATTR
10.4 Industry Chain Structure of Antisense Oligonucleotides Drugs for ATTR

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel
  11.1.1 Direct Channels
  11.1.2 Indirect Channels
11.2 Antisense Oligonucleotides Drugs for ATTR Distributors
11.3 Antisense Oligonucleotides Drugs for ATTR Customer

12 WORLD FORECAST REVIEW FOR ANTISENSE OLIGONUCLEOTIDES DRUGS FOR ATTR BY GEOGRAPHIC REGION

12.1 Global Antisense Oligonucleotides Drugs for ATTR Market Size Forecast by Region
  12.1.1 Global Antisense Oligonucleotides Drugs for ATTR Forecast by Region (2027-2032)
  12.1.2 Global Antisense Oligonucleotides Drugs for ATTR Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Antisense Oligonucleotides Drugs for ATTR Forecast by Type (2027-2032)
12.7 Global Antisense Oligonucleotides Drugs for ATTR Forecast by Application (2027-2032)

13 KEY PLAYERS ANALYSIS

13.1 Akcea Therapeutics
  13.1.1 Akcea Therapeutics Company Information
  13.1.2 Akcea Therapeutics Antisense Oligonucleotides Drugs for ATTR Product Portfolios and Specifications
  13.1.3 Akcea Therapeutics Antisense Oligonucleotides Drugs for ATTR Sales, Revenue, Price and Gross Margin (2021-2026)
  13.1.4 Akcea Therapeutics Main Business Overview
  13.1.5 Akcea Therapeutics Latest Developments
13.2 AstraZeneca
  13.2.1 AstraZeneca Company Information
  13.2.2 AstraZeneca Antisense Oligonucleotides Drugs for ATTR Product Portfolios and Specifications
  13.2.3 AstraZeneca Antisense Oligonucleotides Drugs for ATTR Sales, Revenue, Price and Gross Margin (2021-2026)
  13.2.4 AstraZeneca Main Business Overview
  13.2.5 AstraZeneca Latest Developments
13.3 Ionis Pharmaceuticals
  13.3.1 Ionis Pharmaceuticals Company Information
  13.3.2 Ionis Pharmaceuticals Antisense Oligonucleotides Drugs for ATTR Product Portfolios and Specifications
  13.3.3 Ionis Pharmaceuticals Antisense Oligonucleotides Drugs for ATTR Sales, Revenue, Price and Gross Margin (2021-2026)
  13.3.4 Ionis Pharmaceuticals Main Business Overview
  13.3.5 Ionis Pharmaceuticals Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Antisense Oligonucleotides Drugs for ATTR Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Antisense Oligonucleotides Drugs for ATTR Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Inotersen
Table 4. Major Players of Eplontersen
Table 5. Major Players of Other
Table 6. Global Antisense Oligonucleotides Drugs for ATTR Sales by Type (2021-2026) & (K Units)
Table 7. Global Antisense Oligonucleotides Drugs for ATTR Sales Market Share by Type (2021-2026)
Table 8. Global Antisense Oligonucleotides Drugs for ATTR Revenue by Type (2021-2026) & ($ million)
Table 9. Global Antisense Oligonucleotides Drugs for ATTR Revenue Market Share by Type (2021-2026)
Table 10. Global Antisense Oligonucleotides Drugs for ATTR Sale Price by Type (2021-2026) & (US$/Unit)
Table 11. Global Antisense Oligonucleotides Drugs for ATTR Sale by Application (2021-2026) & (K Units)
Table 12. Global Antisense Oligonucleotides Drugs for ATTR Sale Market Share by Application (2021-2026)
Table 13. Global Antisense Oligonucleotides Drugs for ATTR Revenue by Application (2021-2026) & ($ million)
Table 14. Global Antisense Oligonucleotides Drugs for ATTR Revenue Market Share by Application (2021-2026)
Table 15. Global Antisense Oligonucleotides Drugs for ATTR Sale Price by Application (2021-2026) & (US$/Unit)
Table 16. Global Antisense Oligonucleotides Drugs for ATTR Sales by Company (2021-2026) & (K Units)
Table 17. Global Antisense Oligonucleotides Drugs for ATTR Sales Market Share by Company (2021-2026)
Table 18. Global Antisense Oligonucleotides Drugs for ATTR Revenue by Company (2021-2026) & ($ millions)
Table 19. Global Antisense Oligonucleotides Drugs for ATTR Revenue Market Share by Company (2021-2026)
Table 20. Global Antisense Oligonucleotides Drugs for ATTR Sale Price by Company (2021-2026) & (US$/Unit)
Table 21. Key Manufacturers Antisense Oligonucleotides Drugs for ATTR Producing Area Distribution and Sales Area
Table 22. Players Antisense Oligonucleotides Drugs for ATTR Products Offered
Table 23. Antisense Oligonucleotides Drugs for ATTR Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 24. New Products and Potential Entrants
Table 25. Market M&A Activity & Strategy
Table 26. Global Antisense Oligonucleotides Drugs for ATTR Sales by Geographic Region (2021-2026) & (K Units)
Table 27. Global Antisense Oligonucleotides Drugs for ATTR Sales Market Share Geographic Region (2021-2026)
Table 28. Global Antisense Oligonucleotides Drugs for ATTR Revenue by Geographic Region (2021-2026) & ($ millions)
Table 29. Global Antisense Oligonucleotides Drugs for ATTR Revenue Market Share by Geographic Region (2021-2026)
Table 30. Global Antisense Oligonucleotides Drugs for ATTR Sales by Country/Region (2021-2026) & (K Units)
Table 31. Global Antisense Oligonucleotides Drugs for ATTR Sales Market Share by Country/Region (2021-2026)
Table 32. Global Antisense Oligonucleotides Drugs for ATTR Revenue by Country/Region (2021-2026) & ($ millions)
Table 33. Global Antisense Oligonucleotides Drugs for ATTR Revenue Market Share by Country/Region (2021-2026)
Table 34. Americas Antisense Oligonucleotides Drugs for ATTR Sales by Country (2021-2026) & (K Units)
Table 35. Americas Antisense Oligonucleotides Drugs for ATTR Sales Market Share by Country (2021-2026)
Table 36. Americas Antisense Oligonucleotides Drugs for ATTR Revenue by Country (2021-2026) & ($ millions)
Table 37. Americas Antisense Oligonucleotides Drugs for ATTR Sales by Type (2021-2026) & (K Units)
Table 38. Americas Antisense Oligonucleotides Drugs for ATTR Sales by Application (2021-2026) & (K Units)
Table 39. APAC Antisense Oligonucleotides Drugs for ATTR Sales by Region (2021-2026) & (K Units)
Table 40. APAC Antisense Oligonucleotides Drugs for ATTR Sales Market Share by Region (2021-2026)
Table 41. APAC Antisense Oligonucleotides Drugs for ATTR Revenue by Region (2021-2026) & ($ millions)
Table 42. APAC Antisense Oligonucleotides Drugs for ATTR Sales by Type (2021-2026) & (K Units)
Table 43. APAC Antisense Oligonucleotides Drugs for ATTR Sales by Application (2021-2026) & (K Units)
Table 44. Europe Antisense Oligonucleotides Drugs for ATTR Sales by Country (2021-2026) & (K Units)
Table 45. Europe Antisense Oligonucleotides Drugs for ATTR Revenue by Country (2021-2026) & ($ millions)
Table 46. Europe Antisense Oligonucleotides Drugs for ATTR Sales by Type (2021-2026) & (K Units)
Table 47. Europe Antisense Oligonucleotides Drugs for ATTR Sales by Application (2021-2026) & (K Units)
Table 48. Middle East & Africa Antisense Oligonucleotides Drugs for ATTR Sales by Country (2021-2026) & (K Units)
Table 49. Middle East & Africa Antisense Oligonucleotides Drugs for ATTR Revenue Market Share by Country (2021-2026)
Table 50. Middle East & Africa Antisense Oligonucleotides Drugs for ATTR Sales by Type (2021-2026) & (K Units)
Table 51. Middle East & Africa Antisense Oligonucleotides Drugs for ATTR Sales by Application (2021-2026) & (K Units)
Table 52. Key Market Drivers & Growth Opportunities of Antisense Oligonucleotides Drugs for ATTR
Table 53. Key Market Challenges & Risks of Antisense Oligonucleotides Drugs for ATTR
Table 54. Key Industry Trends of Antisense Oligonucleotides Drugs for ATTR
Table 55. Antisense Oligonucleotides Drugs for ATTR Raw Material
Table 56. Key Suppliers of Raw Materials
Table 57. Antisense Oligonucleotides Drugs for ATTR Distributors List
Table 58. Antisense Oligonucleotides Drugs for ATTR Customer List
Table 59. Global Antisense Oligonucleotides Drugs for ATTR Sales Forecast by Region (2027-2032) & (K Units)
Table 60. Global Antisense Oligonucleotides Drugs for ATTR Revenue Forecast by Region (2027-2032) & ($ millions)
Table 61. Americas Antisense Oligonucleotides Drugs for ATTR Sales Forecast by Country (2027-2032) & (K Units)
Table 62. Americas Antisense Oligonucleotides Drugs for ATTR Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 63. APAC Antisense Oligonucleotides Drugs for ATTR Sales Forecast by Region (2027-2032) & (K Units)
Table 64. APAC Antisense Oligonucleotides Drugs for ATTR Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 65. Europe Antisense Oligonucleotides Drugs for ATTR Sales Forecast by Country (2027-2032) & (K Units)
Table 66. Europe Antisense Oligonucleotides Drugs for ATTR Revenue Forecast by Country (2027-2032) & ($ millions)
Table 67. Middle East & Africa Antisense Oligonucleotides Drugs for ATTR Sales Forecast by Country (2027-2032) & (K Units)
Table 68. Middle East & Africa Antisense Oligonucleotides Drugs for ATTR Revenue Forecast by Country (2027-2032) & ($ millions)
Table 69. Global Antisense Oligonucleotides Drugs for ATTR Sales Forecast by Type (2027-2032) & (K Units)
Table 70. Global Antisense Oligonucleotides Drugs for ATTR Revenue Forecast by Type (2027-2032) & ($ millions)
Table 71. Global Antisense Oligonucleotides Drugs for ATTR Sales Forecast by Application (2027-2032) & (K Units)
Table 72. Global Antisense Oligonucleotides Drugs for ATTR Revenue Forecast by Application (2027-2032) & ($ millions)
Table 73. Akcea Therapeutics Basic Information, Antisense Oligonucleotides Drugs for ATTR Manufacturing Base, Sales Area and Its Competitors
Table 74. Akcea Therapeutics Antisense Oligonucleotides Drugs for ATTR Product Portfolios and Specifications
Table 75. Akcea Therapeutics Antisense Oligonucleotides Drugs for ATTR Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 76. Akcea Therapeutics Main Business
Table 77. Akcea Therapeutics Latest Developments
Table 78. AstraZeneca Basic Information, Antisense Oligonucleotides Drugs for ATTR Manufacturing Base, Sales Area and Its Competitors
Table 79. AstraZeneca Antisense Oligonucleotides Drugs for ATTR Product Portfolios and Specifications
Table 80. AstraZeneca Antisense Oligonucleotides Drugs for ATTR Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 81. AstraZeneca Main Business
Table 82. AstraZeneca Latest Developments
Table 83. Ionis Pharmaceuticals Basic Information, Antisense Oligonucleotides Drugs for ATTR Manufacturing Base, Sales Area and Its Competitors
Table 84. Ionis Pharmaceuticals Antisense Oligonucleotides Drugs for ATTR Product Portfolios and Specifications
Table 85. Ionis Pharmaceuticals Antisense Oligonucleotides Drugs for ATTR Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 86. Ionis Pharmaceuticals Main Business
Table 87. Ionis Pharmaceuticals Latest Developments

List Of Figures

LIST OF FIGURES

Figure 1. Picture of Antisense Oligonucleotides Drugs for ATTR
Figure 2. Antisense Oligonucleotides Drugs for ATTR Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Antisense Oligonucleotides Drugs for ATTR Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Antisense Oligonucleotides Drugs for ATTR Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Antisense Oligonucleotides Drugs for ATTR Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Antisense Oligonucleotides Drugs for ATTR Sales Market Share by Country/Region (2025)
Figure 10. Antisense Oligonucleotides Drugs for ATTR Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Inotersen
Figure 12. Product Picture of Eplontersen
Figure 13. Product Picture of Other
Figure 14. Global Antisense Oligonucleotides Drugs for ATTR Sales Market Share by Type in 2026
Figure 15. Global Antisense Oligonucleotides Drugs for ATTR Revenue Market Share by Type (2021-2026)
Figure 16. Antisense Oligonucleotides Drugs for ATTR Consumed in Hospital and Clinic
Figure 17. Global Antisense Oligonucleotides Drugs for ATTR Market: Hospital and Clinic (2021-2026) & (K Units)
Figure 18. Antisense Oligonucleotides Drugs for ATTR Consumed in Retail Pharmacies
Figure 19. Global Antisense Oligonucleotides Drugs for ATTR Market: Retail Pharmacies (2021-2026) & (K Units)
Figure 20. Antisense Oligonucleotides Drugs for ATTR Consumed in Other
Figure 21. Global Antisense Oligonucleotides Drugs for ATTR Market: Other (2021-2026) & (K Units)
Figure 22. Global Antisense Oligonucleotides Drugs for ATTR Sale Market Share by Application (2025)
Figure 23. Global Antisense Oligonucleotides Drugs for ATTR Revenue Market Share by Application in 2026
Figure 24. Antisense Oligonucleotides Drugs for ATTR Sales by Company in 2026 (K Units)
Figure 25. Global Antisense Oligonucleotides Drugs for ATTR Sales Market Share by Company in 2026
Figure 26. Antisense Oligonucleotides Drugs for ATTR Revenue by Company in 2026 ($ millions)
Figure 27. Global Antisense Oligonucleotides Drugs for ATTR Revenue Market Share by Company in 2026
Figure 28. Global Antisense Oligonucleotides Drugs for ATTR Sales Market Share by Geographic Region (2021-2026)
Figure 29. Global Antisense Oligonucleotides Drugs for ATTR Revenue Market Share by Geographic Region in 2026
Figure 30. Americas Antisense Oligonucleotides Drugs for ATTR Sales 2021-2026 (K Units)
Figure 31. Americas Antisense Oligonucleotides Drugs for ATTR Revenue 2021-2026 ($ millions)
Figure 32. APAC Antisense Oligonucleotides Drugs for ATTR Sales 2021-2026 (K Units)
Figure 33. APAC Antisense Oligonucleotides Drugs for ATTR Revenue 2021-2026 ($ millions)
Figure 34. Europe Antisense Oligonucleotides Drugs for ATTR Sales 2021-2026 (K Units)
Figure 35. Europe Antisense Oligonucleotides Drugs for ATTR Revenue 2021-2026 ($ millions)
Figure 36. Middle East & Africa Antisense Oligonucleotides Drugs for ATTR Sales 2021-2026 (K Units)
Figure 37. Middle East & Africa Antisense Oligonucleotides Drugs for ATTR Revenue 2021-2026 ($ millions)
Figure 38. Americas Antisense Oligonucleotides Drugs for ATTR Sales Market Share by Country in 2026
Figure 39. Americas Antisense Oligonucleotides Drugs for ATTR Revenue Market Share by Country (2021-2026)
Figure 40. Americas Antisense Oligonucleotides Drugs for ATTR Sales Market Share by Type (2021-2026)
Figure 41. Americas Antisense Oligonucleotides Drugs for ATTR Sales Market Share by Application (2021-2026)
Figure 42. United States Antisense Oligonucleotides Drugs for ATTR Revenue Growth 2021-2026 ($ millions)
Figure 43. Canada Antisense Oligonucleotides Drugs for ATTR Revenue Growth 2021-2026 ($ millions)
Figure 44. Mexico Antisense Oligonucleotides Drugs for ATTR Revenue Growth 2021-2026 ($ millions)
Figure 45. Brazil Antisense Oligonucleotides Drugs for ATTR Revenue Growth 2021-2026 ($ millions)
Figure 46. APAC Antisense Oligonucleotides Drugs for ATTR Sales Market Share by Region in 2026
Figure 47. APAC Antisense Oligonucleotides Drugs for ATTR Revenue Market Share by Region (2021-2026)
Figure 48. APAC Antisense Oligonucleotides Drugs for ATTR Sales Market Share by Type (2021-2026)
Figure 49. APAC Antisense Oligonucleotides Drugs for ATTR Sales Market Share by Application (2021-2026)
Figure 50. China Antisense Oligonucleotides Drugs for ATTR Revenue Growth 2021-2026 ($ millions)
Figure 51. Japan Antisense Oligonucleotides Drugs for ATTR Revenue Growth 2021-2026 ($ millions)
Figure 52. South Korea Antisense Oligonucleotides Drugs for ATTR Revenue Growth 2021-2026 ($ millions)
Figure 53. Southeast Asia Antisense Oligonucleotides Drugs for ATTR Revenue Growth 2021-2026 ($ millions)
Figure 54. India Antisense Oligonucleotides Drugs for ATTR Revenue Growth 2021-2026 ($ millions)
Figure 55. Australia Antisense Oligonucleotides Drugs for ATTR Revenue Growth 2021-2026 ($ millions)
Figure 56. China Taiwan Antisense Oligonucleotides Drugs for ATTR Revenue Growth 2021-2026 ($ millions)
Figure 57. Europe Antisense Oligonucleotides Drugs for ATTR Sales Market Share by Country in 2026
Figure 58. Europe Antisense Oligonucleotides Drugs for ATTR Revenue Market Share by Country (2021-2026)
Figure 59. Europe Antisense Oligonucleotides Drugs for ATTR Sales Market Share by Type (2021-2026)
Figure 60. Europe Antisense Oligonucleotides Drugs for ATTR Sales Market Share by Application (2021-2026)
Figure 61. Germany Antisense Oligonucleotides Drugs for ATTR Revenue Growth 2021-2026 ($ millions)
Figure 62. France Antisense Oligonucleotides Drugs for ATTR Revenue Growth 2021-2026 ($ millions)
Figure 63. UK Antisense Oligonucleotides Drugs for ATTR Revenue Growth 2021-2026 ($ millions)
Figure 64. Italy Antisense Oligonucleotides Drugs for ATTR Revenue Growth 2021-2026 ($ millions)
Figure 65. Russia Antisense Oligonucleotides Drugs for ATTR Revenue Growth 2021-2026 ($ millions)
Figure 66. Middle East & Africa Antisense Oligonucleotides Drugs for ATTR Sales Market Share by Country (2021-2026)
Figure 67. Middle East & Africa Antisense Oligonucleotides Drugs for ATTR Sales Market Share by Type (2021-2026)
Figure 68. Middle East & Africa Antisense Oligonucleotides Drugs for ATTR Sales Market Share by Application (2021-2026)
Figure 69. Egypt Antisense Oligonucleotides Drugs for ATTR Revenue Growth 2021-2026 ($ millions)
Figure 70. South Africa Antisense Oligonucleotides Drugs for ATTR Revenue Growth 2021-2026 ($ millions)
Figure 71. Israel Antisense Oligonucleotides Drugs for ATTR Revenue Growth 2021-2026 ($ millions)
Figure 72. Turkey Antisense Oligonucleotides Drugs for ATTR Revenue Growth 2021-2026 ($ millions)
Figure 73. GCC Countries Antisense Oligonucleotides Drugs for ATTR Revenue Growth 2021-2026 ($ millions)
Figure 74. Manufacturing Cost Structure Analysis of Antisense Oligonucleotides Drugs for ATTR in 2026
Figure 75. Manufacturing Process Analysis of Antisense Oligonucleotides Drugs for ATTR
Figure 76. Industry Chain Structure of Antisense Oligonucleotides Drugs for ATTR
Figure 77. Channels of Distribution
Figure 78. Global Antisense Oligonucleotides Drugs for ATTR Sales Market Forecast by Region (2027-2032)
Figure 79. Global Antisense Oligonucleotides Drugs for ATTR Revenue Market Share Forecast by Region (2027-2032)
Figure 80. Global Antisense Oligonucleotides Drugs for ATTR Sales Market Share Forecast by Type (2027-2032)
Figure 81. Global Antisense Oligonucleotides Drugs for ATTR Revenue Market Share Forecast by Type (2027-2032)
Figure 82. Global Antisense Oligonucleotides Drugs for ATTR Sales Market Share Forecast by Application (2027-2032)
Figure 83. Global Antisense Oligonucleotides Drugs for ATTR Revenue Market Share Forecast by Application (2027-2032)